These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 19292836)

  • 1. Effects of orlistat on visceral fat after liposuction.
    Montoya T; Monereo S; Olivar J; Iglesias P; Díaz P
    Dermatol Surg; 2009 Mar; 35(3):469-74. PubMed ID: 19292836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Short-term administration of orlistat reduced daytime triglyceridemia in obese women with the metabolic syndrome.
    Tzotzas T; Samara M; Constantinidis T; Tziomalos K; Krassas G
    Angiology; 2007; 58(1):26-33. PubMed ID: 17351155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of orlistat therapy on weight reduction in morbidly obese patients after implantation of the Swedish adjustable gastric band.
    Zoss I; Piec G; Horber FF
    Obes Surg; 2002 Feb; 12(1):113-7. PubMed ID: 11868286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cholesterol lowering effect of dietary weight loss and orlistat treatment--efficacy and limitations.
    Erdmann J; Lippl F; Klose G; Schusdziarra V
    Aliment Pharmacol Ther; 2004 Jun; 19(11):1173-9. PubMed ID: 15153170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Orlistat and sibutramine beyond weight loss.
    Mannucci E; Dicembrini I; Rotella F; Rotella CM
    Nutr Metab Cardiovasc Dis; 2008 Jun; 18(5):342-8. PubMed ID: 17928208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial.
    Harrison SA; Fecht W; Brunt EM; Neuschwander-Tetri BA
    Hepatology; 2009 Jan; 49(1):80-6. PubMed ID: 19053049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Orlistat for obesity: benefits beyond weight loss.
    Hsieh CJ; Wang PW; Liu RT; Tung SC; Chien WY; Chen JF; Chen CH; Kuo MC; Hu YH
    Diabetes Res Clin Pract; 2005 Jan; 67(1):78-83. PubMed ID: 15620437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The long-term influence of orlistat on dietary intake in obese subjects with components of metabolic syndrome.
    Svendsen M; Helgeland M; Tonstad S
    J Hum Nutr Diet; 2009 Feb; 22(1):55-63. PubMed ID: 19192027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the effects of sibutramine and orlistat on obese, poorly-controlled type 2 diabetic patients.
    Chou KM; Huang BY; Fanchiang JK; Chen CH
    Chang Gung Med J; 2007; 30(6):538-46. PubMed ID: 18350737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Orlistat increases serum paraoxonase activity in obese patients.
    Audikovszky M; Pados G; Seres I; Harangi M; Fülöp P; Katona E; Illyés L; Winkler G; Katona EM; Paragh G
    Nutr Metab Cardiovasc Dis; 2007 May; 17(4):268-73. PubMed ID: 17134960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term weight loss decreases the nontraditional cardiovascular risk factors interleukin-18 and matrix metalloproteinase-9 in obese subjects.
    Madsen EL; Bruun JM; Skogstrand K; Hougaard DM; Christiansen T; Richelsen B
    Metabolism; 2009 Jul; 58(7):946-53. PubMed ID: 19409578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A structured weight management programme can achieve improved functional ability and significant weight loss in obese patients with chronic kidney disease.
    Cook SA; MacLaughlin H; Macdougall IC
    Nephrol Dial Transplant; 2008 Jan; 23(1):263-8. PubMed ID: 17977872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in body composition with weight loss: obese subjects randomized to surgical and medical programs.
    Dixon JB; Strauss BJ; Laurie C; O'Brien PE
    Obesity (Silver Spring); 2007 May; 15(5):1187-98. PubMed ID: 17495195
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of orlistat treatment interruption on weight and associated metabolic parameters.
    Owen K; Svacina S
    Prague Med Rep; 2006; 107(4):394-400. PubMed ID: 17402552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Who will lose weight on sibutramine and orlistat? Psychological correlates for treatment success.
    Elfhag K; Finer N; Rössner S
    Diabetes Obes Metab; 2008 Jun; 10(6):498-505. PubMed ID: 17593239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abdominal adiposity and liver fat content 3 and 12 months after gastric banding surgery.
    Heath ML; Kow L; Slavotinek JP; Valentine R; Toouli J; Thompson CH
    Metabolism; 2009 Jun; 58(6):753-8. PubMed ID: 19375765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduction of body weight and co-morbidities by orlistat: The XXL--Primary Health Care Trial.
    Wirth A
    Diabetes Obes Metab; 2005 Jan; 7(1):21-7. PubMed ID: 15642072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of orlistat on fecal fat, fecal biliary acids, and colonic cell proliferation in obese subjects.
    Ahnen DJ; Guerciolini R; Hauptman J; Blotner S; Woods CJ; Wargovich MJ
    Clin Gastroenterol Hepatol; 2007 Nov; 5(11):1291-9. PubMed ID: 17920338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bioelectric impedance analysis and quality of life after body-contouring procedures in plastic surgery.
    Smeets R; Noah EM; Seiferth NY; Gröger A; Bozkurt A; Fuchs PC; Ulrich D; Pallua N
    J Plast Reconstr Aesthet Surg; 2009 Jul; 62(7):940-5. PubMed ID: 18550462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An RCT of metformin versus orlistat for the management of obese anovulatory women.
    Metwally M; Amer S; Li TC; Ledger WL
    Hum Reprod; 2009 Apr; 24(4):966-75. PubMed ID: 19095663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.